YONMIRI
DEAD

Serial Number

90860823

Owner

Celgene Corporation

Attorney

Xiomara Triana

Filing Date

Aug 2, 2021

Add to watchlist:

No watchlists yet
View on USPTO

YONMIRI Trademark

Serial Number: 90860823

YONMIRI is a trademark filed by Celgene Corporation on August 2, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Celgene Corporation (883 trademarks)

7 Powder Horn Drive
Warren, NJ 07059

Entity Type: 03

Trademark Details

Filing Date

August 2, 2021

Registration Date

Not Registered

Published for Opposition

May 30, 2023

Goods & Services

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Feb 26, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Feb 26, 2024 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 25, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 30, 2023 NPUB
PUBLISHED FOR OPPOSITION
May 30, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 10, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 27, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 26, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 26, 2023 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 26, 2023 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 28, 2022 GNFN
FINAL REFUSAL E-MAILED
Oct 28, 2022 GNFR
FINAL REFUSAL WRITTEN
Oct 28, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 27, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 27, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 27, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 2, 2022 GNRN
NON-FINAL ACTION E-MAILED
May 2, 2022 GNRT
NON-FINAL ACTION WRITTEN
May 2, 2022 CNRT
ASSIGNED TO EXAMINER
Apr 29, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 28, 2021 NWOS
NEW APPLICATION ENTERED
Aug 5, 2021 NWAP